CLN6 rabbit pAb
ENT-A6507
Description
| REF | ENT-A6507 |
|---|---|
| Category | Antibody Polyclonal |
| Description | CLN6 rabbit pAb |
| Source | Rabbit |
| Applications | WB;IHC;IF;ELISA |
| Reactivity | Human;Rat;Mouse; |
| Reactivity | Human;Rat;Mouse; |
| Dilution | Western Blot: 1/500 – 1/2000. Immunohistochemistry: 1/100 – 1/300. ELISA: 1/40000. Not yet tested in other applications. |
| Immunogen | The antiserum was produced against synthesized peptide derived from human CLN6. AA range:221-270 |
| Storage Stability | -20°C/1 year |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1 mg/ml |
| Observed Band KD | 40kD |
| Human Gene ID | 54982 |
| Human Swiss Prot Nº | Q9NWW5 |
| Subcellular Location | Endoplasmic reticulum membrane ; Multi-pass membrane protein . Endoplasmic reticulum . |
Other Name: CLN6; Ceroid-lipofuscinosis neuronal protein 6; Protein CLN6
Background: This gene is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely encode proteins involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function. [provided by RefSeq, Oct 2008],